scholarly article | Q13442814 |
P50 | author | Ken Fujise | Q93046258 |
P2093 | author name string | Decha Pinkaew | |
Perumal Thiagarajan | |||
Patuma Sinthujaroen | |||
Preedakorn Chunhacha | |||
Hasseri Halim | |||
P2860 | cites work | Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells | Q24563090 |
Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation | Q24627354 | ||
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks | Q24633890 | ||
Lamin proteolysis facilitates nuclear events during apoptosis | Q24681695 | ||
Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance | Q27693875 | ||
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis | Q28592044 | ||
Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
GARP2 accelerates retinal degeneration in rod cGMP-gated cation channel β-subunit knockout mice. | Q30398618 | ||
ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice | Q30511960 | ||
Atherosclerotic plaque rupture--pathologic basis of plaque stability and instability | Q33643432 | ||
Toll-like receptor 7 deficiency protects apolipoprotein E-deficient mice from diet-induced atherosclerosis | Q33678336 | ||
Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers | Q34019342 | ||
Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects | Q34120974 | ||
Tumor necrosis factor-alpha in human arterial wall with atherosclerosis | Q34700760 | ||
Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety | Q34805121 | ||
Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein | Q35213271 | ||
Early growth response 1 (Egr1) regulates cholesterol biosynthetic gene expression | Q35313420 | ||
Atherosclerotic Plaque Stability Is Affected by the Chemokine CXCL10 in Both Mice and Humans | Q35582482 | ||
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents | Q35783487 | ||
A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor | Q35827283 | ||
Morelloflavone, a biflavonoid inhibitor of migration-related kinases, ameliorates atherosclerosis in mice | Q35921239 | ||
Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. | Q53471537 | ||
Ticagrelor | Q61668621 | ||
A new platelet function test | Q67295105 | ||
Identification of active tissue factor in human coronary atheroma | Q71571184 | ||
Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects | Q73013573 | ||
Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis | Q73596679 | ||
Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression | Q74309008 | ||
Pathology of the vulnerable plaque | Q83187650 | ||
Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells | Q83305041 | ||
Macrophage inflammatory protein-1β and fibrinogen are synergistic predictive markers of prognosis of intermediate coronary artery lesions | Q83540593 | ||
Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment | Q85167435 | ||
Protein detection by Simple Western™ analysis | Q85312527 | ||
Light transmission aggregometry | Q86519312 | ||
Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea | Q88792905 | ||
Assessment of a flow cytometry technique for studying signaling pathways in platelets: Monitoring of VASP phosphorylation in clinical samples | Q91373933 | ||
Failure to Recognize Novelty after Extended Methamphetamine Self-Administration Results from Loss of Long-Term Depression in the Perirhinal Cortex | Q36059937 | ||
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease | Q36221940 | ||
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. | Q36330189 | ||
Fortilin potentiates the peroxidase activity of Peroxiredoxin-1 and protects against alcohol-induced liver damage in mice. | Q36423249 | ||
Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice. | Q36940644 | ||
Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers | Q37077147 | ||
Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis | Q37225795 | ||
Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis | Q37314369 | ||
Fortilin reduces apoptosis in macrophages and promotes atherosclerosis | Q37342158 | ||
Rewiring of jasmonate and phytochrome B signalling uncouples plant growth-defense tradeoffs. | Q37502046 | ||
Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice | Q37527691 | ||
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. | Q37562606 | ||
Platelet P2Y12 receptor inhibition by thienopyridines: status and future | Q37579228 | ||
Targeting paraoxonase-1 in atherosclerosis | Q38097853 | ||
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance | Q38207389 | ||
Novel antiplatelet agents in acute coronary syndrome | Q38257119 | ||
Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines | Q38694069 | ||
Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. | Q39093174 | ||
Hepatocellular toxicity of clopidogrel: mechanisms and risk factors | Q39139225 | ||
Long-term use of ticagrelor in patients with prior myocardial infarction | Q40263764 | ||
Interleukin-6 exacerbates early atherosclerosis in mice | Q40793841 | ||
Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis | Q41728164 | ||
Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. | Q42498203 | ||
Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor | Q42760647 | ||
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy | Q42910350 | ||
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. | Q43873602 | ||
Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study | Q44447076 | ||
Hepatic gene expression profiling reveals perturbed calcium signaling in a mouse model lacking both LDL receptor and Apobec1 genes | Q44512715 | ||
Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice | Q45042448 | ||
Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice | Q45140669 | ||
Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques | Q45343506 | ||
Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment | Q45365025 | ||
Pro-inflammatory role of platelets in hypertension-mediated end-organ damage : Editorial to: "Inhibition of Platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis" by L.-X. Jia et al. | Q45729733 | ||
Detection and localization of tumor necrosis factor in human atheroma | Q46152807 | ||
The mechanism and risk factors of clopidogrel-induced liver injury | Q46625831 | ||
Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. | Q46707933 | ||
Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF-alpha | Q46773827 | ||
A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. | Q46778536 | ||
Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: The Tromsø Study | Q49916343 | ||
Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. | Q50986493 | ||
Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. | Q52543322 | ||
P275 | copyright license | Creative Commons CC0 License | Q6938433 |
P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
P433 | issue | 6 | |
P921 | main subject | clopidogrel | Q410237 |
P304 | page(s) | e0218934 | |
P577 | publication date | 2019-06-26 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel | |
P478 | volume | 14 |